Overview

Phase 1b Study to Evaluate the Addition of a Pembrolizumab Treatment After Treatment With CYAD-101 With a FOLFOX Preconditioning in Metastatic Colorectal Cancer Patients

Status:
Not yet recruiting

Trial end date:
2038-05-25

Target enrollment:

Participant gender:

Summary

The purpose of the CYAD-101-002 study is to assess the safety and clinical activity of CYAD-101 in patients with unresectable metastatic colorectal cancer administered concurrently with FOLFOX chemotherapy, followed by pembrolizumab treatment.

Phase:

Phase 1

Details

Lead Sponsor:

Celyad Oncology SA

Collaborator:

Merck Sharp & Dohme Corp.

Treatments:

Pembrolizumab